ATE463505T1 - Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren - Google Patents

Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Info

Publication number
ATE463505T1
ATE463505T1 AT01274166T AT01274166T ATE463505T1 AT E463505 T1 ATE463505 T1 AT E463505T1 AT 01274166 T AT01274166 T AT 01274166T AT 01274166 T AT01274166 T AT 01274166T AT E463505 T1 ATE463505 T1 AT E463505T1
Authority
AT
Austria
Prior art keywords
toll
receptor
ligands
methods
tlr5
Prior art date
Application number
AT01274166T
Other languages
English (en)
Inventor
Alan Aderem
Fumitaka Hayashi
David Underhill
Adrian Ozinsky
Kelly Smith
Original Assignee
Inst Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23094403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463505(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Systems Biology filed Critical Inst Systems Biology
Application granted granted Critical
Publication of ATE463505T1 publication Critical patent/ATE463505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01274166T 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren ATE463505T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547701P 2001-04-20 2001-04-20
PCT/US2001/022978 WO2002085933A1 (en) 2001-04-20 2001-07-20 Toll-like receptor 5 ligands and methods of use

Publications (1)

Publication Number Publication Date
ATE463505T1 true ATE463505T1 (de) 2010-04-15

Family

ID=23094403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274166T ATE463505T1 (de) 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Country Status (5)

Country Link
US (3) US7915381B2 (de)
EP (1) EP1379552B2 (de)
AT (1) ATE463505T1 (de)
DE (1) DE60141773D1 (de)
WO (1) WO2002085933A1 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
EP1536832A2 (de) * 2002-09-03 2005-06-08 Fondation Eurovacc Flagellin peptide als adjuvantien für impfstoffe
EP1599726A4 (de) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selektive modulation von tlr-vermittelter biologischer aktivität
EP1631687A2 (de) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
BRPI0413558A (pt) * 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
AU2004268625B2 (en) * 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
AR046046A1 (es) * 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005040208A2 (en) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
WO2005042017A1 (en) * 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CA2545825A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (de) 2003-11-14 2008-10-22 3M Innovative Properties Co Oximsubstituierte imidazoringverbindungen
CA2547020C (en) * 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
JP2007517035A (ja) * 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (de) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
KR20050073865A (ko) 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20080248068A1 (en) * 2004-05-07 2008-10-09 Hans-Gustaf Ljunggren Use of Flagellin as an Adjuvant for Vaccine
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20090137390A1 (en) * 2004-06-30 2009-05-28 Eric Wendell Triplett Materials and methods for enhancing nitrogen fixation in plants
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
WO2006039701A1 (en) * 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
EP1819364A4 (de) * 2004-12-08 2010-12-29 3M Innovative Properties Co Immunmodulatorische zusammensetzungen, kombinationen und verfahren
EP1827489B1 (de) * 2004-12-16 2012-10-31 Wake Forest University Health Sciences Verwendung von flagellin zur tumorimmuntherapie
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2460534A1 (de) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellinverwandte Polypeptide und deren Verwendungen
HU227285B1 (en) * 2004-12-29 2011-01-28 Mta Enzimologiai Intezet Modified flagellins and flagellar filaments useful as receptors and processes for producing same
JP5543068B2 (ja) * 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1831221B1 (de) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen
EP2374474A1 (de) 2005-01-19 2011-10-12 Vaxinnate Corporation Zusammensetzungen mit Pathogen-assoziierten Molekularstrukturen und Antigene sowie ihre Verwendungen zur Stimulation einer Immunantwort
AU2006210392A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
WO2006085411A1 (ja) * 2005-02-10 2006-08-17 National University Corporation Hokkaido University 免疫応答を惹起するための新規アジュバントおよびその利用
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
DE102005020798A1 (de) * 2005-04-28 2006-11-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von TLR- und/oder Nod2-Liganden zur Herstellung eines Arzneimittels zur Behandlung einer Krankheit des zentralen Nervensystems
KR100804507B1 (ko) 2005-05-17 2008-02-20 전남대학교산학협력단 플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
US8137930B2 (en) * 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062043A1 (en) * 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
WO2007098371A2 (en) * 2006-02-16 2007-08-30 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008063369A2 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
US8236327B2 (en) * 2007-02-09 2012-08-07 Industry Foundation Of Chonnam National University Modified flagellin improved toll-like receptor 5 stimulating activity
WO2009079564A2 (en) * 2007-12-17 2009-06-25 Emory University Immunogenic compositions and methods of use thereof
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
CA2739454C (en) * 2008-10-03 2018-05-01 Emory University Methods for the treatment of graft-versus-host disease
WO2010080007A2 (ko) * 2009-01-09 2010-07-15 부산대학교 산학협력단 Ｔｏｌｌ 유사수용체２ 리간드로서 기능하는 그람양성균 유래의 리포단백질
EP2408475B1 (de) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin-fusionsproteine und ihre verwendung zur auslösung von immunantworten gegen pseudomonas aeruginosa
US20100322957A1 (en) * 2009-05-22 2010-12-23 Aderem Alan A Secretion-related bacterial proteins for nlrc4 stimulation
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
ES2769326T3 (es) 2010-02-05 2020-06-25 Univ Cornell Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor
GB2481267B (en) 2010-06-15 2016-04-20 Univ Leicester Assay for determining the risk of a toll-like receptor containing foodstuff for causing systemic inflammation in vivo
BR112012033121B1 (pt) 2010-06-25 2019-08-20 Institut Pasteur De Lille Métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
WO2012040164A2 (en) 2010-09-24 2012-03-29 Emory University Tlr5 ligands, therapeutic methods, and compositions related thereto
WO2012097012A1 (en) 2011-01-10 2012-07-19 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
WO2013177440A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Ordered flagellin array as an immunostimulant
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
EP3400953A1 (de) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirinpolypeptid und immunmodulation
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ME03487B (de) 2016-03-04 2020-01-20 4D Pharma Plc Zusammensetzungen mit bakteriellen blautia-stämmen zur behandlung von viszeraler überempfindlichkeit
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (de) 2017-05-24 2022-11-30 4D Pharma Research Limited Zusammensetzungen mit bakterienstamm
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
SG11201911430PA (en) * 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
WO2019018768A1 (en) 2017-07-20 2019-01-24 Spogen Biotech Inc. BIOACTIVE POLYPEPTIDES FOR PLANT PROTECTION, GROWTH AND PRODUCTIVITY ENHANCEMENTS
US12440536B2 (en) 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2023275292A2 (en) 2021-06-30 2023-01-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosol composition for pulmonary delivery of flagellin
WO2024035137A1 (ko) * 2022-08-10 2024-02-15 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
WO2024085375A1 (ko) * 2022-10-19 2024-04-25 전남대학교산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용
WO2025172452A1 (en) 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain
WO2026022365A1 (en) * 2024-07-26 2026-01-29 Elanco Animal Health Gmbh Mammalian il-4/il-13/flagellin constructs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5888810A (en) * 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6030624A (en) * 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
ATE335513T1 (de) * 1998-10-16 2006-09-15 Gen Hospital Corp Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
WO2000071720A1 (en) * 1999-05-25 2000-11-30 Immunex Corporation Il-1 eta dna and polypeptides
US6740487B1 (en) * 1999-06-10 2004-05-25 University Of Iowa Research Foundation Variant TLR4 nucleic acid and uses thereof
EP1290160B1 (de) * 2000-04-28 2006-03-29 Immunex Corporation Humanische pellino-polypeptide
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
FR2812304B1 (fr) * 2000-07-31 2004-12-17 Bio Merieux Complexe de lipo-viro-particules, procede de preparation et applications
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Also Published As

Publication number Publication date
EP1379552B2 (de) 2014-11-19
US7915381B2 (en) 2011-03-29
US20030044429A1 (en) 2003-03-06
US9085616B2 (en) 2015-07-21
DE60141773D1 (de) 2010-05-20
EP1379552B1 (de) 2010-04-07
WO2002085933A1 (en) 2002-10-31
EP1379552A1 (de) 2004-01-14
US20110008318A1 (en) 2011-01-13
US20120269855A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
ATE463505T1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
WO2005037190A3 (en) Multiplex vaccines
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
MY125202A (en) Vaccine
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
ATE357930T1 (de) Immunmodulierende zusammensetzungen die eine an antigen gebundene immunstimulierende sequenz enthalten und deren verwendungen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
MXPA05014016A (es) Proteinas portadoras para vacunas.
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
ATE426412T1 (de) Adjuvante influenza-vakzine
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE382690T1 (de) Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties